Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1819-1830

  Kim, Jung Won ^a   Kim, Jung Ryul ^a   Yi, SoJeong ^a   Shin, Kwang Hee ^a   Shin, Hyun Suk ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Kim, Dal Hyun ^b   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Chong Kun Dang Research Institute   (South Korea)

Author keywords

Lobeglitazone; Pharmacokinetics; PPAR agonist; Tolerability

Indexed keywords

LOBEGLITAZONE;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CATHETER INFECTION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG MARKETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KOREA; LARYNX PAIN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL STIFFNESS; NAUSEA; NORMAL HUMAN; PILOT STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINORRHEA; SINGLE DRUG DOSE; SOMNOLENCE; SUPRAVENTRICULAR PREMATURE BEAT; THORAX PAIN; URINALYSIS;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PLACEBOS; PPAR GAMMA; PYRIMIDINES; REFERENCE VALUES; THIAZOLIDINEDIONES;

EID: 82855162713     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.023     Document Type: Article

References (32)

1. Henry R.R. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 2003, 25:B47-B63.
2. Evans J.L., Lin J.J., Goldfine I.D. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr Diabetes Rev 2005, 1:299-307.
3. Varma S., Boyle L.L., Varma M.R., Piatt G.A. Controlling the ABCs of diabetes in clinical practice: a community-based endocrinology practice experience. Diabetes Res Clin Pr 2008, 80:89-95.
4. Balakumar P., Rose M., Ganti S.S., et al. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol Res 2007, 56:91-98.
5. Jurado J., Ybarra J., Solanas P., et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Prac 2009, 21:140-148.
6. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
7. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
8. Watkins P.J. ABC of diabetes - cardiovascular disease, hypertension, and lipids. BMJ 2003, 326:874-876.
9. Tenenbaum A., Motro M., Fisman E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14.
10. Skrumsager B.K., Nielsen K.K., Muller M., et al. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol 2003, 43:1244-1256.
11. Barish G.D., Narkar V.A., Evans R.M. PPAR δ: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590-597.
12. Jones D. Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 2010, 9:668-669.
13. Kim B.Y., Ahn J.B., Lee H.W., et al. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur J Med Chem 2004, 39:433-447.
14. Kim B.Y., Ahn J.B., Lee H.W., et al. Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives. Chem Pharm Bull (Tokyo) 2003, 51:276-285.
15. Lee H.W., Kim B.Y., Ahn J.B., et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 2005, 40:862-874.
16. Lee H.W., Ahn J.B., Kang S.K., et al. Process development and scale-up of PPAR alpha/gamma dual agonist lobeglitazone sulfate (CKD-501). Org Process Res Dev 2007, 11:190-199.
17. Lee J.H., Woo Y.A., Hwang I.C., et al. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. J Pharm Biomed Anal 2009, 50:872-877.
18. Sauerberg P., Bury P.S., Mogensen J.P., et al. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J Med Chem 2003, 46:4883-4894.
19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice Efficacy guidelines, Accessed April 24, 2010. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
20. Ethical Principles for Medical Research Involving Human Subjects Accessed April 24, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
21. Boyd R., Leigh B., Stuart P. Capillary versus venous bedside blood glucose estimations. Emerg Med J 2005, 22:177-179.
22. Shin H.-S., Seo H.B., Shin J.S., et al. Quantitative determination of CKD-501 by high turbulence liquid chromatography - tandem mass spectrometry in human plasma and urine. 17th International Mass Spectrometry Conference 2006, 2006. IMSC, Prague, Czech Republic, MoP-105.
23. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications 2007, CRC Press, Baco Raton. 4th ed.
24. Hummel J., McKendrick S., Brindley C., French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009, 8:38-49.
25. Smith B.P., Vandenhende F.R., DeSante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000, 17:1278-1283.
26. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26.
27. Veber D.F., Johnson S.R., Cheng H.Y., et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002, 45:2615-2623.
28. Faber K.N., Muller M., Jansen P.L. Drug transport proteins in the liver. Adv Drug Deliv Rev 2003, 55:107-124.
29. Johnston G.D., Finch M.B., McNeill J.A., Shanks R.G. A comparison of the cardiovascular effects of (+)-sotalol and (+/-)-sotalol following intravenous administration in normal volunteers. Br J Clin Pharmacol 1985, 20:507-510.
30. Drayer D.E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther 1986, 40:125-133.
31. Gumbhir-Shah K., Kellerman D.J., DeGraw S., et al. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998, 38:1096-1106.
32. Rippley R.K., Yan K.X., Matthews N.D., et al. Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist. J Clin Pharmacol 2007, 47:323-333.